[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361091-105":59,"doc-detail-361091-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ret-receptor-tyrosine-kinase-promotes-breast-cancer-metastasis-to-the-brain-and-ret-inhibitors-pralsetinib-and-selpercatinib-suppress-breast-cancer-brain-metastases","RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases","","Patients with breast cancer brain metastases (BCBM) show poor outcomes due to limited biological insight and few therapies that cross the blood-brain barrier. This study evaluates RET receptor tyrosine kinase in BCBM and tests brain-penetrant RET inhibition. RET activation is elevated in patient samples and brain-tropic cell models and correlates with worse brain metastasis-free survival. In mice, RET overexpression and intracranial implantation accelerate brain tumor formation, while pralsetinib and selpercatinib reduce viability, promote apoptosis, and suppress metastasis progression in vivo.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ret-receptor-tyrosine-kinase-promotes-breast-cancer-metastasis-to-the-brain-and-ret-inhibitors-pralsetinib-and-selpercatinib-suppress-breast-cancer-brain-metastases/361091/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ret-receptor-tyrosine-kinase-promotes-breast-cancer-metastasis-to-the-brain-and-ret-inhibitors-pralsetinib-and-selpercatinib-suppress-breast-cancer-brain-metastases/361091.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does RET play in breast cancer brain metastases (BCBM)?","Question",{"text":113,"@type":114},"RET activation is elevated in BCBM patient samples and in brain-tropic breast cancer cell lines, and higher RET pathway activation associates with worse brain metastasis-free survival.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do pralsetinib and selpercatinib affect brain-tropic breast cancer cells?",{"text":118,"@type":114},"Selective BBB-permeable RET inhibition using pralsetinib and selpercatinib reduces cell viability, enhances apoptosis, and attenuates migration of brain-tropic breast cancer cells in vitro.",{"name":120,"@type":111,"acceptedAnswer":121},"Does inhibiting RET prevent brain metastasis in animal models?",{"text":122,"@type":114},"In mouse models of multiorgan metastases and brain tumor formation, RET inhibition prevents circulating tumor cells from forming brain metastases and suppresses the growth of intracranially implanted tumors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},361091,1790196595,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nRET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases  \nAngelina T. Regua1,6, Shivani Bindal1,6, Mariana K. Najjar2,3,6, Phi-Long Tran2,3, Joshua Cha2,3, Syed Shahmeer Shams1 and Hui-Wen Lo 1,2,3,4,5 ✉  \n© The Author(s) 2026  \n\n|  |  |  |\n| --- | --- | --- |\n|  | Patients with breast cancer brain metastases (BCBM) exhibit dismal prognosis, largely due to the insufﬁcient biological understanding and the scarcity of therapeutics that can penetrate the blood-brain barrier (BBB) . This study was focused on Rearranged during transfection (RET) receptor tyrosine kinase that has been implicated in non-small cell lung cancer (NSCLC) and thyroid cancer. Here, we report that RET activation is elevated in patient BCBM samples compared to matched primary tumors (N = 30), and in three brain-tropic breast cancer cell lines compared to the parental lines. High RET pathway activation is associated with worse brain metastasis-free survival in patients with HER2-enriched and triple-negative breast cancer (TNBC). Using TNBC cells with ectopic RET overexpression, we demonstrated that RET strongly promoted their preferential metastasis to the brain in mice with intracardiac injections of tumor cells. Using intracranial tumor implantation of the isogenic lines, we found that RET signiﬁcantly enhanced the formation and progression of brain tumors in vivo. Moreover, we observed that selective BBB-permeable RET inhibition using Pralsetinib and Selpercatinib, FDA-approved for NSCLC and thyroids cancer, signiﬁcantly reduced cell viability, enhanced apoptosis, and attenuated migration of brain-tropic breast cancer cells in vitro. Using two mouse studies modeling multiorgan metastases and breast tumor formation in the brain, we observed that RET inhibition signiﬁcantly prevented the circulating tumor cells from forming brain metastases and suppressed the growth of intracranially implanted tumor cells. Together, our ﬁndings |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | demonstrated that RET functions as a novel mediator of BCBM and that RET inhibitors showed promising efﬁcacy for BCBM. |  |\n|  |  |  |\n|  |  |  |\n|  | Cell Death and Disease (2026) 17:679 ; [https://doi.org/10.1038/s41419-026-08890-z](https://doi.org/10.1038/s41419-026-08890-z) |  |\n|  |  |  |\n\nINTRODUCTION  \nBreast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer related deaths among American women [1, 2]. Among the various subtypes, HER2-enriched and triplenegative breast cancer (TNBC) subtypes are the most aggressive, exhibiting the marked propensity for distant metastases, particularly to the brain [3, 4]. Breast cancer brain metastases (BCBM) occur in approximately 10-30% of metastatic breast cancer cases and are associated with dismal prognoses, with a median survival time of 7.9 months, which is signiﬁcantly lower than the median survival for metastases to the lung (25 months), liver (31 months), or bone (36 months) [4, 5]. Currently, there is no recommended standard of care for BCBM, and the treatment landscape remains severely limited due to the lack of actionable molecular targets and the challenge of delivering therapeutics across the blood-brain and blood-tumor barriers (BBB/BTB) [6, 7]. These limitations underscore the urgent need to identify novel therapeutic candidates in BCBM that are actionable with brain-penetrant compounds.  \nRearranged during transfection (RET) is a receptor tyrosine kinase encoded by the RET gene and is prone to forming oncogenic RET fusions in various solid cancer types [8] . RET is activated upon binding of its cognate ligand, glial cell line-derived neurotrophic factor (GDNF), to the co-receptor GDNF family receptor alpha-1 (GFR1α), which fa","cbCaitAISsrFnMAB","https://ap.wps.com/l/cbCaitAISsrFnMAB","pdf",3280136,16,"English","# Introduction\n## RET biology and activation mechanisms\n## Current treatment limitations for BCBM\n## Rationale for targeting RET","[{\"question\":\"What role does RET play in breast cancer brain metastases (BCBM)?\",\"answer\":\"RET activation is elevated in BCBM patient samples and in brain-tropic breast cancer cell lines, and higher RET pathway activation associates with worse brain metastasis-free survival.\"},{\"question\":\"How do pralsetinib and selpercatinib affect brain-tropic breast cancer cells?\",\"answer\":\"Selective BBB-permeable RET inhibition using pralsetinib and selpercatinib reduces cell viability, enhances apoptosis, and attenuates migration of brain-tropic breast cancer cells in vitro.\"},{\"question\":\"Does inhibiting RET prevent brain metastasis in animal models?\",\"answer\":\"In mouse models of multiorgan metastases and brain tumor formation, RET inhibition prevents circulating tumor cells from forming brain metastases and suppresses the growth of intracranially implanted tumors.\"}]","RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases | PDF",1790143094,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35ae6b8442b2cf9af8508118bf6c44c1.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0bd7e0377ef42dd8af3cb194370af51.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e27b1422b8b992fa7442050915914af6.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef453e942c4d6bf6dcf9f939c304cdf5.webp",980,1301]